PL374439A1 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
PL374439A1
PL374439A1 PL03374439A PL37443903A PL374439A1 PL 374439 A1 PL374439 A1 PL 374439A1 PL 03374439 A PL03374439 A PL 03374439A PL 37443903 A PL37443903 A PL 37443903A PL 374439 A1 PL374439 A1 PL 374439A1
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL03374439A
Other languages
English (en)
Polish (pl)
Inventor
Avigdor Levanon
Rachel Ben-Levy
Daniel Plaksin
Esther Szanton
Yocheved Hagai
Mar-Chaim Hagit Hoch
Original Assignee
Savient Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals, Inc. filed Critical Savient Pharmaceuticals, Inc.
Publication of PL374439A1 publication Critical patent/PL374439A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL03374439A 2002-07-01 2003-06-30 Antibodies and uses thereof PL374439A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18903202A 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
PL374439A1 true PL374439A1 (en) 2005-10-17

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374439A PL374439A1 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof

Country Status (12)

Country Link
EP (1) EP1534332A4 (fr)
JP (1) JP2005536199A (fr)
KR (1) KR20060011925A (fr)
CN (1) CN1678347A (fr)
AU (1) AU2003263764A1 (fr)
BR (1) BR0312483A (fr)
CA (1) CA2491363A1 (fr)
IL (1) IL166063A0 (fr)
MX (1) MXPA05000272A (fr)
PL (1) PL374439A1 (fr)
RU (1) RU2005101621A (fr)
WO (1) WO2004003166A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
AR048840A1 (es) * 2004-05-11 2006-05-31 Boehringer Ingelheim Int Epitopes inductores de la muerte de las celulas t
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
ES2694239T3 (es) 2010-11-12 2018-12-19 Gentium S.R.L. Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD)
CA2838952C (fr) 2011-06-13 2020-11-24 Stefan Bassarab Anticorps anti-psgl-1 et leurs utilisations
CA2874960C (fr) 2012-06-22 2021-05-18 Gentium S.P.A. Procede a base d'euglobuline pour la determination de l'activite biologique de defibrotide
EP3026122A1 (fr) 2014-11-27 2016-06-01 Gentium S.p.A. Procédé à base cellulaire pour déterminer la puissance de défibrotide
KR101896751B1 (ko) * 2015-12-01 2018-10-04 주식회사 엘지화학 열가소성 수지, 이의 제조방법 및 이를 포함하는 열가소성 수지 조성물
EP3824287A1 (fr) * 2018-07-20 2021-05-26 Pierre Fabre Médicament Récepteur pour vista
CN111715409B (zh) * 2020-07-01 2021-07-23 中南大学 一种微细粒方铅矿的组合铅抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774419C (en) * 1998-10-30 2005-03-03 Genetics Institute, Llc Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
AU2001249421B2 (en) * 2000-03-24 2006-09-07 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor

Also Published As

Publication number Publication date
EP1534332A4 (fr) 2006-11-22
MXPA05000272A (es) 2005-09-20
WO2004003166A3 (fr) 2005-03-10
BR0312483A (pt) 2005-08-09
IL166063A0 (en) 2006-01-15
WO2004003166A2 (fr) 2004-01-08
CN1678347A (zh) 2005-10-05
KR20060011925A (ko) 2006-02-06
CA2491363A1 (fr) 2004-01-08
AU2003263764A1 (en) 2004-01-19
EP1534332A2 (fr) 2005-06-01
JP2005536199A (ja) 2005-12-02
RU2005101621A (ru) 2005-11-20

Similar Documents

Publication Publication Date Title
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (fr) Anticorps anti-addl et leurs utilisations
HK1248731A1 (zh) 免疫球蛋白變體及其用途
EP1551877A4 (fr) Anticorps anti-taci et utilisations de ceux-ci
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
EP1539941A4 (fr) Adzymes et leurs utilisations
EP1494693A4 (fr) Anticorps specifiques au cripto
IL172871A0 (en) Rg1 antibodies and uses thereof
PL375405A1 (en) Antibodies
EP1699485A4 (fr) Anticorps anti-hydroxylase et utilisations
IL172510A0 (en) Antibodies and uses thereof
IL166063A0 (en) Antibodies and uses thereof
EP1589033A4 (fr) Anticorps et utilisation de ce dernier
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003249533A8 (en) Neoplasm specific antibodies and uses thereof
AU2003298739A8 (en) Intermedin and its uses
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0226878D0 (en) Antibodies
AU2003216442A8 (en) Enkurin and uses thereof
EP1627888A4 (fr) Anticorps et son utilisation
GB0227080D0 (en) Antibodies and uses thereof
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof
EP1557430A4 (fr) Anticorps et utilisation dudit anticorps
AU2003263751A8 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)